These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 11365830)
1. Drug failure and HIV resistance create frustrating scenarios for clinicians. Murphy MJ Fac Notes (New Orleans La); 1998; 10(5):1-3. PubMed ID: 11365830 [TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
3. HIV drug resistance and the other causes of treatment failure. Schouten JT STEP Perspect; 1997; 9(3):5-8. PubMed ID: 11364937 [TBL] [Abstract][Full Text] [Related]
4. HIV-1 drug resistance assays in clinical management. Martinez-Picado J; D'Aquila R AIDS Clin Care; 1998 Nov; 10(11):81-5, 87-8. PubMed ID: 11365861 [TBL] [Abstract][Full Text] [Related]
5. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471 [TBL] [Abstract][Full Text] [Related]
6. Your next nightmare: 28% of new HIV cases may be drug-resistant. AIDS Alert; 1999 Dec; 14(12):133-7. PubMed ID: 11366987 [TBL] [Abstract][Full Text] [Related]
7. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Naeger LK; Margot NA; Miller MD Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416 [TBL] [Abstract][Full Text] [Related]
8. Genotypic resistance tests for the management of structured therapeutic interruptions after multiple drug failure. Montroni M; Monforte AD Scand J Infect Dis Suppl; 2003; 106():79-81. PubMed ID: 15000591 [TBL] [Abstract][Full Text] [Related]
9. Viral resistance: how it may affect treatment options. Biehler GV Body Posit; 1998 Jun; 11(6):42-3. PubMed ID: 11365610 [TBL] [Abstract][Full Text] [Related]
10. Genotypic resistance tests for the clinical management of patients with primary HIV infection. Narciso P; Lazzarin A Scand J Infect Dis Suppl; 2003; 106():66-70. PubMed ID: 15000588 [TBL] [Abstract][Full Text] [Related]
11. Overview on HIV-1-related drug resistance: from theory to clinical practice. Moroni M; Balotta C; Rusconi S J Biol Regul Homeost Agents; 1998; 12(1-2 Suppl):15-8. PubMed ID: 9689573 [No Abstract] [Full Text] [Related]
12. Therapeutic options or antiretroviral anarchy? Mascolini M J Int Assoc Physicians AIDS Care; 1999 Jan; 5(1):10-30. PubMed ID: 11366158 [TBL] [Abstract][Full Text] [Related]
13. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment. Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132 [TBL] [Abstract][Full Text] [Related]